Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Jean-Pierre VacherPhilippe J.R. KokMiguel Trefaut RodriguesAlbertina LimaTomas HrbekFernanda WerneckSophie ManziChristophe ThébaudAntoine Fouquet
• Organismes : Centre de Recherche sur la Biodiversité et l'Environnement Vrije Universiteit Brussel [Bruxelles] University of Lódź = Uniwersytet Łódzki Universidade Federal de São Paulo = Federal University of São Paulo Instituto Nacional de Pesquisas da Amazônia = National Institute of Amazonian Research Universidade Federal do Amazonas Instituto Nacional de Pesquisas da Amazônia = National Institute of Amazonian Research Centre de Recherche sur la Biodiversité et l'Environnement Centre de Recherche sur la Biodiversité et l'Environnement Evolution et Diversité Biologique Centre de Recherche sur la Biodiversité et l'Environnement
• Publié dans Molecular Phylogenetics and Evolution le 31/10/2020

---

Résumé : Two main landscapes emerge from the Guiana Shield: the highlands to the west called the Pantepui region and the Amazonian lowlands to the east, both harbouring numerous endemic species. With 32 currently recognized species, the genus Anomaloglossus stands out among Neotropical frogs as one that diversified only within the Guiana Shield both in the highlands and the lowlands. We present a time-calibrated phylogeny obtained by using combined mitogenomic and nuclear DNA, which suggests that the genus originates from Pantepui where extant lineages started diversifying around 21 Ma, and subsequently (ca. 17 Ma) dispersed during the Miocene Climatic Optimum to the lowlands of the eastern Guiana Shield where the ability to produce endotrophic tadpoles evolved. Further diversification within the lowlands in the A. stepheni group notably led to an evolutionary reversal toward exotrophy in one species group during the late Miocene, followed by reacquisition of endotrophy during the Pleistocene. These successive shifts of reproductive mode seem to have accompanied climatic oscillations. Long dry periods might have triggered evolution of exotrophy, whereas wetter climates favoured endotrophic forms, enabling colonization of terrestrial habitats distant from water. Acquisition, loss, and reacquisition of endotrophy makes Anomaloglossus unique among frogs and may largely explain the current species diversity. The micro evolutionary processes involved in these rapid shifts of reproductive mode remain to be revealed.

---

Fichiers liés : MPE-D-22-00365_R1_no_suppl.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Sindy SimIgor Lima MaldonadoPierre CastelnauLaurent BarantinWissam El-HageFrédéric AnderssonJean-Philippe Cottier
• Organismes : Centre Hospitalier Régional Universitaire de Tours Imaging, Brain & Neuropsychiatry Imaging, Brain & Neuropsychiatry Imaging, Brain & Neuropsychiatry Imaging, Brain & Neuropsychiatry Centre Hospitalier Régional Universitaire de Tours Imaging, Brain & Neuropsychiatry Centre Hospitalier Régional Universitaire de Tours Imaging, Brain & Neuropsychiatry
• Publié dans Journal de Neuroradiologie / Journal of Neuroradiology le 26/10/2020

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/03/2024
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoHanspeter NaegeliFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiMichele ArdizzoneAna CamargoGiacomo de SanctisSilvia FedericiAntonio FernandezAndrea GennaroJosé Ángel Gómez RuizTilemachos GoumperisPaschalina GrammatikouDafni Maria KagkliPaolo LenziFranco Maria NeriNikoletta PapadopoulouTommaso Raffaello
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Lloyd IzardNadège FonvieilleCamille MerlandPhilippe KoubbiDavid NeriniJérémie HabasqueAnne Lebourges-DhaussyClaire Lo MonacoGildas RoudautFrancesco d'OvidioJean-Benoît CharrassinCédric Cotté
• Organismes : Processus et interactions de fine échelle océanique Institut méditerranéen d'océanologie Sorbonne Université - Faculté des Sciences et ingénierie - UFR Terre, Environnement, Biodiversité Laboratoire Ressources Halieutiques de Boulogne Sorbonne Université - Faculté des Sciences et ingénierie - UFR Terre, Environnement, Biodiversité Institut méditerranéen d'océanologie Laboratoire des Sciences de l'Environnement Marin (LEMAR) Laboratoire des Sciences de l'Environnement Marin (LEMAR) Cycles biogéochimiques marins : processus et perturbations Laboratoire des Sciences de l'Environnement Marin (LEMAR) Processus et interactions de fine échelle océanique Processus et interactions de fine échelle océanique Processus et interactions de fine échelle océanique
• Publié dans Journal of Marine Systems le 25/10/2020

---

Résumé : The pelagic zone is home to a large diversity of organisms such as macrozooplankton and micronekton (MM), connecting the surface productive waters to the mesopelagic layers (200-1000 m) through diel vertical migrations (DVM). Active acoustics complement net sampling observations by detecting sound-scattering layers (SL) of organisms, allowing to monitor the MM dynamics with a high spatio-temporal resolution. Multifrequency analyses are a pertinent approach to better integrate the rich diversity of organisms composing SLs and their respective dynamics. However, analysing simultaneously emitted acoustic signals with distinct depth ranges and separating spatial from temporal variability is challenging and needs adapted tools to be fully exploited. This study examines the pelagic realm in a transition zone between the Southern Ocean and the subtropical Indian Ocean, crossing the Saint-Paul and Amsterdam islands' natural reserve. We extended a Multivariate Functional Principal Component Analysis (mfPCA) to analyse the joint vertical variation of five frequencies from two oceanographic cruises (2016 and 2022), allowing the decomposition of the acoustic dataset into orthogonal vertical modes (VM) of variability. We found the first VM to be linked to the temporal variability due to DVM, while the following majorly depict patterns in spatial distribution. Overall, from the subantarctic to the subtropical zones, we observed (i) enrichment of densities in the surface layer (0-100 m), (ii) a decrease in densities in the intermediate layer during the daytime (100-300 m) and (iii) the apparition of an intensive deep scattering layer on the 38 kHz. We explored VMs' connection with in -situ environmental conditions by clustering our observations into three distinct environmental-acoustic regions. These regions were compared with vertically integrated nautical area scattering coefficient distribution, a proxy for marine organisms' biomass. Additionally, we analysed species assemblage changes from complementary cruises to further elucidate the observed acoustic distribution. We show that the mfPCA method is promising to better integrate the pelagic horizontal, vertical and temporal dimensions which is a step towards further investigating the control of the environment on the distribution and structuring of pelagic communities.

---

Fichiers liés : Full_text_MarSys.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Xavier DeffieuxMarie-Aimée Perrouin-VerbeSandrine Campagne-LoiseauLaurence DononAmélie LevesqueJérome RigaudNadja StivaletAurélien VenaraThibault ThubertAdrien VidartPierre-Olivier BossetChristine Revel-DelhomJean-Philippe LucotJean François Hermieu
• Organismes : Université Paris-Saclay AP-HP - Hôpital Antoine Béclère [Clamart] Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Estaing [Clermont-Ferrand] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Université Paris Cité Université d'Angers Centre Hospitalier Universitaire d'Angers Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Foch [Suresnes] Hôpital Foch [Suresnes] Hôpital Foch [Suresnes] Université catholique de Lille Université Paris Cité
• Publié dans European Journal of Obstetrics & Gynecology and Reproductive Biology le 30/10/2020

---

Résumé : Complications associated with pelvic organ prolapse (POP) surgery using a synthetic non-absorbable mesh are uncommon (<5%) but may be severe and may hugely diminish the quality of life of some women. In drawing up these multidisciplinary clinical practice recommendations, the French National Authority for Health (Haute Autorité de santé, HAS) conducted an exhaustive review of the literature concerning the diagnosis, prevention, and management of complications associated with POP surgery using a synthetic mesh. Each recommendation for practice was allocated a grade (A,B or C; or expert opinion (EO)), which depends on the level of evidence (clinical practice guidelines).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Philippe Van de PerreGabriella ScarlattiPenny L MooreJean-Pierre MolesNicolas NagotThorkild TylleskärGlenda GrayAmeena Goga
• Organismes : Pathogenesis and Control of Chronic and Emerging Infections IRCCS Ospedale San Raffaele [Milan, Italy] University of the Witwatersrand [Johannesburg] National Institute for Communicable Diseases [Johannesburg] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections University of Bergen South African Medical Research Council [Cape Town, South Africa] South African Medical Research Council [Cape Town, South Africa] University of Pretoria [South Africa]
• Publié dans Immunity, Inflammation and Disease le 26/10/2020

---

Résumé : Passive immunoprophylaxis with broadly neutralizing monoclonal antibodies (bNAbs) could be a game changer in the prevention of human immunodeficiency virus (HIV) acquisition. The prevailing view is that available resources should be focused on identifying a fixed combination of at least three bNAbs for universal use in therapeutic and preventive protocols, regardless of target populations or routes of transmission. HIV transmission through breastfeeding is unique: it involves free viral particles and cell‐associated virus from breast milk and, in the case of acute/recent maternal infection, a viral population with restricted Env diversity. HIV transmission through breastfeeding in high incidence/prevalence areas could potentially be eliminated by subcutaneous administration to all newborns of one or two long‐acting bNAbs with extended breadth, high potency, and effector properties (ADCC, phagocytosis) against circulating HIV strains.

---

Fichiers liés : Immunity Inflam Disease - 2024 - Van de Perre - Preventing breast milk HIV transmission using broadly neutralizing.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Lina JeantinEdouard JanuelPierre LabaugeÉlisabeth MaillartJérôme de SèzeHélène ZéphirJean PelletierPhilippe KerschenDamien BiottiOlivier HeinzlefLaurent GuillotonCaroline BensaMarie ThéaudinSandra VukusicOlivier CasezAude MauroussetDavid-Axel LaplaudEric BergerChristine Lebrun-FrenayBertrand BourrePierre BrangerBruno StankoffPierre ClavelouEric ThouvenotEric ManchonThibault MoreauFrançois SellalMickaël ZedetCaroline PapeixCéline Louapre
• Organismes : Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut des Neurosciences de Montpellier Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] CIC Strasbourg Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Centre Hospitalier Régional Universitaire [CHU Lille] Service de neurophysiologie clinique [Hôpital de la Timone - APHM] Hôpital Kirchberg [Luxembourg] Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Association des Neurologues Libéraux de Langue Française Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Université de Lausanne = University of Lausanne Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Team 5 : Neuroinflammation, mechanisms, therapeutic options (NEMO) CHU Rouen Service de Neurologie [CHU Caen] CHU Saint-Antoine [AP-HP] CHU Clermont-Ferrand Institut de Génomique Fonctionnelle Université de Strasbourg CHU Henri Mondor [Créteil] Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
• Publié dans Multiple Sclerosis Journal le 31/10/2020

---

Résumé : Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.

---

Fichiers liés : covisep_hal.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Mathieu MévelVirginie PichardMohammed BouzelhaDimitri Alvarez-DortaPierre-Alban LalysNathalie ProvostMarine AllaisAlexandra MendesElodie LandagarayJean‐baptiste DucloyerEstelle ToublancAnne GalyNicole BrumentGaëlle M. LefevreSébastien G. GouinCarolina IsiegasGuylène Le MeurT. CroninCaroline Le GuinerMichel WeberPhilippe P. MoullierEduard AyusoSebastien G. GouinOumeya Adjali
• Organismes : Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Coave Therapeutics Coave Therapeutics Coave Therapeutics Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089
• Publié dans Molecular Therapy - Methods and Clinical Development le 26/10/2020

---

Résumé : Inherited retinal diseases are a leading and untreatable cause of blindness and are therefore candidate diseases for gene therapy. Recombinant vectors derived from adeno-associated virus (rAAV) are currently the most promising vehicles for in vivo therapeutic gene delivery to the retina. However, there is a need for novel AAV-based vectors with greater efficacy for ophthalmic applications, as underscored by recent reports of dose-related inflammatory responses in clinical trials of rAAV-based ocular gene therapies. Improved therapeutic efficacy of vectors would allow for decreases in the dose delivered, with consequent reductions in inflammatory reactions. Here, we describe the development of new rAAV vectors using bioconjugation chemistry to modify the rAAV capsid, thereby improving the therapeutic index. Covalent coupling of a mannose ligand, via the formation of a thiourea bond, to the amino groups of the rAAV capsid significantly increases vector transduction efficiency of both rat and nonhuman primate retinas. These optimized rAAV vectors have important implications for the treatment of a wide range of retinal diseases.

---

Fichiers liés : 1-s2.0-S2329050124000032-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Delphine DouilletAndrea PenalozaDamien ViglinoJean-Jacques BanihachemiAnmar AbboodiMathilde HelderléEmmanuel MontassierFréderic BalenChristian BriceSaïd LaribiThibault DuchenoyPhilippe VivesLouis SoulatNicolas MarjanovicThomas MoumnehDominique SavaryJérémie RiouPierre-Marie Roy
• Organismes : Hypoxie et PhysioPathologie
• Publié dans The Lancet le 02/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Maya HitesClément R MassonnaudEva Larranaga LapiqueDrifa BelhadiSimon JamardFrançois GoehringerFrançois DanionJean ReignierNathalie de CastroDenis GarotKarine LacombeViolaine TolsmaEmmanuel FaureDenis MalvyThérèse StaubJohan CourjonFrance RoblotAnne Ma Dyrhol RiisePaul LeturnierGuillaume Martin-BlondelClaire RogerKarolina AkinosoglouVincent Le MoingLionel PirothPierre SellierXavier LescureMarius TrøseidPhilippe ClevenberghOlav DalgardSébastien GallienMarie GousseffPaul LoubetFanny Vardon-BounesClotilde ViséeLeila BelkhirÉlisabeth Botelho-NeversAndré CabiéAnastasia KotanidouFanny LanternierElisabeth RouveixSusana SilvaGuillaume ThieryPascal PoignardGuislaine CarcelainAlpha DialloNoémie MercierVida TerzicMaude Bouscambert-DuchampAlexandre GaymardMary-Anne TrabaudGrégory DestrasLaurence JossetNicolas BillardThi-Hong-Lien HanJérémie GuedjSandrine Couffin-CadierguesAline DechanetChristelle DelmasHélène EsperouClaire Fougerou-LeurentSoizic Le MestreAnabelle MétoisMarion NoretIsabelle BallySebastián Dergan-DylonSarah TubianaOuifiya KalifNathalie BergaudBenjamin LeveauJoe EustaceRichard GreilEdit HajduMonika HalanovaJose-Artur PaivaAnna PiekarskaJesus Rodriguez BañoKristian TonbyMilan TrojánekSotirios TsiodrasSerhat UnalCharles BurdetDominique CostagliolaYazdan YazdanpanahNathan Peiffer-SmadjaFrance MentréFlorence Ader
• Organismes : Université libre de Bruxelles = Free University of Brussels Hôpital Erasme = Erasmus Hospital = Erasmus Ziekenhuis Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université libre de Bruxelles = Free University of Brussels Hôpital Erasme = Erasmus Hospital = Erasmus Ziekenhuis AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Nancy Hôpitaux Universitaires de Strasbourg Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [AP-HP] Génomes, biologie cellulaire et thérapeutiques Centre Hospitalier Régional Universitaire de Tours Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois] Centre Hospitalier Régional Universitaire [CHU Lille] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier de Luxembourg [Luxembourg] Université Côte d'Azur Centre Hospitalier Universitaire de Nice Pharmacologie des anti-infectieux et antibiorésistance [U 1070] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Oslo University Hospital [Oslo] Hôpital Hôtel-Dieu [CHU Nantes] Institut Toulousain des Maladies Infectieuses et Inflammatoires Service Maladies infectieuses et tropicales [CHU Toulouse] Centre Hospitalier Universitaire de Nîmes General University Hospital of Patras CHU Montpellier = Montpellier University Hospital Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [AP-HP] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution Oslo University Hospital [Oslo] Centre Hospitalier Universitaire Brugmann [Bruxelles] Université libre de Bruxelles = Free University of Brussels Akershus University Hospital [Lørenskog] University of Oslo IMRB - VHC/"Viruses-Hepatology-Cancers" [Créteil] CHU Henri Mondor [Créteil] Centre hospitalier Bretagne Atlantique (Morbihan) Virulence Bactérienne et Infections Chroniques Centre Hospitalier Universitaire de Nîmes Pôle Anesthésie Réanimation [CHU de Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires hospital universitaire de Mons-Hainaut Cliniques Universitaires Saint-Luc [Bruxelles] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Physiopathologie et biothérapies des infections muqueuses [CIRI] Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Centre d'Investigation Clinique Antilles-Guyane National and Kapodistrian University of Athens Evangelismos Athens General Hospital Hôpital Necker - Enfants Malades [AP-HP] Hôpital Ambroise Paré [AP-HP] Universidade do Porto = University of Porto Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Institut de biologie structurale Centre d'Investigation Clinique [Grenoble] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Immunologie humaine, physiopathologie & immunothérapie Hôpital Robert Debré ANRS - Maladies infectieuses émergentes ANRS - Maladies infectieuses émergentes ANRS - Maladies infectieuses émergentes Hospices Civils de Lyon Centre International de Recherche en Infectiologie Hospices Civils de Lyon Centre International de Recherche en Infectiologie Hôpital de la Croix-Rousse [CHU - HCL] Hospices Civils de Lyon Hospices Civils de Lyon AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution Institut national de la santé publique - National Institute of Public Health [Bujumbura, Burundi] Pôle de Recherche Clinique [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Institut national de la santé publique - National Institute of Public Health [Bujumbura, Burundi] Pôle de Recherche Clinique [Paris] Institut national de la santé publique - National Institute of Public Health [Bujumbura, Burundi] Pôle de Recherche Clinique [Paris] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] ANRS - Maladies infectieuses émergentes AP-HP - Hôpital Bichat - Claude Bernard [Paris] Réseau national de recherche clinique en infectiologie Institut de biologie structurale Institut de biologie structurale AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hospices Civils de Lyon Hospices Civils de Lyon University College Cork Paracelsus Medizinische Privatuniversität = Paracelsus Medical University University of Szeged [Szeged] Pavol Jozef Šafárik University in Košice Centro Hospitalar Universitário São João = São João University Hospital [Porto] Universidade do Porto = University of Porto Medical University of Łódź Hospital Universitario Virgen Macarena [Séville] Oslo University Hospital [Oslo] University Hospital Bulovka National and Kapodistrian University of Athens “Attikon” University Hospital Faculty of Medicine [Hacettepe University] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Institut Pierre Louis d'Epidémiologie et de Santé Publique Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Imperial College London Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre International de Recherche en Infectiologie Hôpital de la Croix-Rousse [CHU - HCL]
• Publié dans Journal of Infection le 23/10/2020

---

Résumé : No abstract available

---

Fichiers liés : 1-s2.0-S0163445324000549-main.pdf

---

Source